Celgene Corporation to Present at the 31st Annual J.P. Morgan Healthcare Conference

Celgene CorporationJacqualyn A. Fouse, Ph.D, 908-673-9956EVP, Chief Financial OfficerorPatrick E. Flanigan III, 908-673-9969VP, Investor Relations

today announced its presentation at the 31 Annual J.P. Morgan Healthcare Conference on January 7, 2013 at 11:00a.m. E.T. will be webcast live and will be available in the investor relations section of the company’s Web site at . Celgene management will provide an overview of the company.

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company’s Web site at .

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.